Home/Filings/4/0001493152-25-008106
4//SEC Filing

Murali Ramachandran 4

Accession 0001493152-25-008106

CIK 0001962011other

Filed

Feb 23, 7:00 PM ET

Accepted

Feb 24, 6:52 PM ET

Size

5.1 KB

Accession

0001493152-25-008106

Insider Transaction Report

Form 4
Period: 2025-01-01
Murali Ramachandran
VP of Research and Development
Transactions
  • Award

    COMMON STOCK

    2025-01-01+14,000147,057 total
Footnotes (2)
  • [F1]Represents 14,000 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 14,000,000 RSUs are scheduled to vest in one third increments on each of 01/01/2025, 09/16/2025, and 09/16/2026. Accordingly, 4,667 RSUs have vested as of the date hereof.
  • [F2]Consists of (1) 137,724 shares of common stock and (2) 9,333 RSUs which remain subject to vesting.

Documents

1 file

Issuer

Kairos Pharma, LTD.

CIK 0001962011

Entity typeother

Related Parties

1
  • filerCIK 0001870016

Filing Metadata

Form type
4
Filed
Feb 23, 7:00 PM ET
Accepted
Feb 24, 6:52 PM ET
Size
5.1 KB